Katherine Tynan

Strategic Advisor for Board & C-Level Executives | Board Director | Advisory Board Member | Healthcare | Clinical Diagnostics| Devices| Genomics | Digital Health | Business Growth Strategist |

📍 United States🔄 Updated September 2026💼 2 investments📅 4 years investing🗓 Last invested Apr 2023
VC🌍 United States
2
Total investments
0
Early stage
0
Mid stage
0
Late stage
4y
Years active

Portfolio

1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Apr 2023
GMDx Genomics has developed a genomic Platform Technology that uses validated algorithms to provide a detailed analysis of an individual’s Innate Immune Fitness. The analysis of an individual’s Innate Immune Fitness provides the diagnostic ability to predict an individual’s capability to mount an effective Adaptive Immune Response in a range of disease states. ​ GMDx analyses a Whole Genome Sequence (WGS) from any laboratory source and provides a comprehensive genomic profile on that individual that is in full compliance with all health information privacy regulations. ​ GMDx utilises an industry-leading framework developed by technology stack partners Applied Precision Medicine that is built on the Oracle Autonomous Cloud.
Experience · 2 entries
All (2)
Investments (2)
Board (1)
2023
Board Member
Apr 2023
GMDx Genomics has developed a genomic Platform Technology that uses validated algorithms to provide a detailed analysis of an individual’s Innate Immune Fitness. The analysis of an individual’s Innate Immune Fitness provides the diagnostic ability to predict an individual’s capability to mount an effective Adaptive Immune Response in a range of disease states. ​ GMDx analyses a Whole Genome Sequence (WGS) from any laboratory source and provides a comprehensive genomic profile on that individual that is in full compliance with all health information privacy regulations. ​ GMDx utilises an industry-leading framework developed by technology stack partners Applied Precision Medicine that is built on the Oracle Autonomous Cloud.
2022
Angel Investor
Jun 2022
INVESTING IN HIGH-PERFORMING, WOMEN-LED COMPANIES Currently investing from Astia Fund I - a $32M Series A/B fund that is sector and geography agnostic. For twenty years, Astia has carved a unique path to source, screen and invest in the top performing companies. Astia’s proprietary Expert Sift™ deal sourcing and screening process is a robust, data-driven methodology that uses best-in-class tools and wisdom-of-the-crowd techniques to eliminate bias. To successfully address the intersectionality of race and gender, Astia established a clear focus on investing in women of color. Grounded in deep domain expertise, exceptional investment performance, a belief in the value of women as leaders and a proprietary investment process, Astia invests via a family of funds. Throughout its twenty years, Astia has paved the way for investors to align human values with investment rigor. Understanding the fundamentals of change, Astia has built an institution to last. Through a variety of investment vehicles, Astia enables investment at all stages of private company growth. With an acute understanding of the unique challenges of high-growth, Astia ensures portfolio success. We are entrepreneur-centric and hands-on. By investing with Astia, Limited Partners expand their legacy of impact. Founded by tech pioneer Catherine Muther in 1998, Astia has never wavered from its fundamental commitment to level the investment playing field. Still today, less than 10 percent of VC investments are made into companies that include even one woman leader. We believe in investment as a force for change.